JPWO2019245038A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019245038A5
JPWO2019245038A5 JP2020525826A JP2020525826A JPWO2019245038A5 JP WO2019245038 A5 JPWO2019245038 A5 JP WO2019245038A5 JP 2020525826 A JP2020525826 A JP 2020525826A JP 2020525826 A JP2020525826 A JP 2020525826A JP WO2019245038 A5 JPWO2019245038 A5 JP WO2019245038A5
Authority
JP
Japan
Prior art keywords
positive
cells
pharmaceutical composition
antibody
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020525826A
Other languages
English (en)
Japanese (ja)
Other versions
JP7788711B2 (ja
JPWO2019245038A1 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2019/024753 external-priority patent/WO2019245038A1/ja
Publication of JPWO2019245038A1 publication Critical patent/JPWO2019245038A1/ja
Publication of JPWO2019245038A5 publication Critical patent/JPWO2019245038A5/ja
Priority to JP2023209708A priority Critical patent/JP2024015377A/ja
Application granted granted Critical
Publication of JP7788711B2 publication Critical patent/JP7788711B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020525826A 2018-06-22 2019-06-21 複合状態を有する細胞混合物を用いた、免疫寛容を誘導する抗体、及び誘導されたリンパ球、また誘導されたリンパ球を用いる細胞治療剤及び治療法 Active JP7788711B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023209708A JP2024015377A (ja) 2018-06-22 2023-12-12 複合状態を有する細胞混合物を用いた、免疫寛容を誘導する抗体、及び誘導されたリンパ球、また誘導されたリンパ球を用いる細胞治療剤及び治療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018119001 2018-06-22
JP2018119001 2018-06-22
PCT/JP2019/024753 WO2019245038A1 (ja) 2018-06-22 2019-06-21 複合状態を有する細胞混合物を用いた、免疫寛容を誘導する抗体、及び誘導されたリンパ球、また誘導されたリンパ球を用いる細胞治療剤及び治療法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023209708A Division JP2024015377A (ja) 2018-06-22 2023-12-12 複合状態を有する細胞混合物を用いた、免疫寛容を誘導する抗体、及び誘導されたリンパ球、また誘導されたリンパ球を用いる細胞治療剤及び治療法

Publications (3)

Publication Number Publication Date
JPWO2019245038A1 JPWO2019245038A1 (ja) 2021-07-08
JPWO2019245038A5 true JPWO2019245038A5 (https=) 2022-06-21
JP7788711B2 JP7788711B2 (ja) 2025-12-19

Family

ID=68984082

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020525826A Active JP7788711B2 (ja) 2018-06-22 2019-06-21 複合状態を有する細胞混合物を用いた、免疫寛容を誘導する抗体、及び誘導されたリンパ球、また誘導されたリンパ球を用いる細胞治療剤及び治療法
JP2023209708A Pending JP2024015377A (ja) 2018-06-22 2023-12-12 複合状態を有する細胞混合物を用いた、免疫寛容を誘導する抗体、及び誘導されたリンパ球、また誘導されたリンパ球を用いる細胞治療剤及び治療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023209708A Pending JP2024015377A (ja) 2018-06-22 2023-12-12 複合状態を有する細胞混合物を用いた、免疫寛容を誘導する抗体、及び誘導されたリンパ球、また誘導されたリンパ球を用いる細胞治療剤及び治療法

Country Status (9)

Country Link
US (1) US12397054B2 (https=)
EP (1) EP3811952A4 (https=)
JP (2) JP7788711B2 (https=)
KR (2) KR20210024048A (https=)
CN (1) CN112601531A (https=)
AU (1) AU2019288683A1 (https=)
CA (1) CA3104797A1 (https=)
TW (1) TWI832869B (https=)
WO (1) WO2019245038A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023190942A1 (https=) * 2022-03-31 2023-10-05

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU748533B2 (en) 1997-06-11 2002-06-06 United States Of America As Represented By The Secretary Of The Navy, The Composition and method to prevent graft rejection and other counter-adaptive T lymphocyte mediated immune responses
JP2003033175A (ja) * 2001-07-23 2003-02-04 Keio Gijuku 選択的免疫応答抑制を誘導する末梢血樹状細胞サブセット
US7485314B2 (en) * 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
JP2007131598A (ja) 2005-11-14 2007-05-31 Kurosu Biotech:Kk 腎移植拒絶反応抑制剤
EP2212350B1 (en) * 2007-10-26 2013-08-28 Governing Council of the University of Toronto Treating chronic viral infection by targetting TIM-3
MX2010004892A (es) * 2007-10-31 2010-08-10 Scripps Research Inst Terapia de combinacion para tratar infecciones virales persistentes.
CN106432474A (zh) * 2010-03-12 2017-02-22 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途
CN104854101B (zh) 2012-11-06 2018-05-01 上海复尚慧创医药研究有限公司 Alk激酶抑制剂
RS58351B1 (sr) 2013-03-15 2019-03-29 Shire Viropharma Inc C1-inh kompozicije i postupci za prevenciju i lečenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze
US20160046715A1 (en) * 2013-05-17 2016-02-18 Abwiz Bio, Inc. T regulatory cells and uses thereof
EP2870972A1 (en) 2013-11-06 2015-05-13 Paul Scherrer Institut Mini-gastrin analogue, in particular for use in CCK2 receptor positive tumour diagnosis and/or treatment
JP2023033175A (ja) 2021-08-26 2023-03-09 日星電気株式会社 発熱部材の保護構造、及び液体処理装置

Similar Documents

Publication Publication Date Title
Sobhani et al. CTLA-4 in regulatory T cells for cancer immunotherapy
WO2017130223A3 (en) A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
Boettcher et al. Development of CAR T cell therapy in children—A comprehensive overview
JP2020505001A5 (https=)
FI4063397T3 (fi) Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi
JP2020512973A5 (https=)
JP2016196468A5 (https=)
MX2023006482A (es) Anticuerpos biespecificos especificos para un receptor de tnf coestimulador.
PH12021550662A1 (en) Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously
HRP20211794T1 (hr) Humana antitijela za pd-1
CR20200014A (es) Molécula de polipéptido con especificidad dual mejorada
PH12018500766A1 (en) Bispecific antibodies with tetravalency for a costimulatory tnf receptor
EP3812398A3 (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
FI4050034T3 (fi) Cd3:een sitoutuvia vasta-aineita
JP2016531907A5 (https=)
RU2018107802A (ru) Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин
EP3625255A4 (en) NOVEL MONOCLONAL ANTIBODIES AGAINST CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4)
WO2012092376A3 (en) Comprehensive monoclonal antibody generation
Drabek et al. Expression cloning and production of human heavy-chain-only antibodies from murine transgenic plasma cells
WO2014012085A3 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
NZ733025A (en) Bcma chimeric antigen receptors
PH12020551124A1 (en) Bispecific antibody
EP4458419A3 (en) Methods for expanding antigen-specific car-t cells, compositions and uses related thereto
Pytlik et al. Current immunotherapy approaches in non-hodgkin lymphomas
JPWO2019245038A5 (https=)